Regkirona Claimed to be Effective in Reducing the Severity and Death Risk of Covid-19

Regkirona

To stop the Covid-19’s spread in the body, we needed drugs that prevent the severity after being infected with Covid-19. One way to stop that risk is Regkirona monoclonal antibody therapy.

Dr. Raymond Tjandrawinata, Executive Director of Dexa Laboratories of Biomolecular Sciences, said this drug was built from convalescent plasma collected from Covid-19 survivors in South Korea.

“The patient’s blood is then filtered, using special technology to produce the Regkirona monoclonal antibody,” he said.

He said the therapeutic drug for Covid-19 patients uses monoclonal antibodies so they can neutralize the coronavirus that enters the body.

“Because it works to neutralize the virus, it can be classified as an antiviral monoclonal antibody,” he added.

In 3rd phase clinical trial, Dr. Raymond claimed Regkirona can reduce hospitalization and death’s risk in Covid-19 patients by 72 percent.

“If it could prevent for up to 28 days, he (the patient) does not need hospitalization, doesn’t die, so that’s a 72 percent decrease,” he said.

He also claimed that Regkirona could neutralize all corona variants from Delta, Alpha, Beta, to Gamma.

Raymond said this therapy is used in Covid-19 patients with mild or asymptomatic symptoms.

“This treatment is carried out for patients who are still mild (symptoms), not many symptoms, have not used a ventilator. Because this drug isn’t to treat the severe, we prevent the severe ones,” he said.

He explained this drug is given in one infusion. For this reason, therapy can only be done in a hospital or clinic and must be supervised by a doctor.

“The work is done within 90 minutes. And the antibodies work directly in the body,” he explained.

Because there are antibodies that enter the body, side effects such as fever or the risk of allergies will appear. However, from a study, only a small number of patients experienced it.

Unlike the other Covid-19 drugs, Regkirona monoclonal antibody therapy doesn’t cause drug interactions or leave reactions in the liver and kidneys.

Patients who can do this therapy are diagnosed as positive for Covid-19 with mild symptoms, such as cough, runny nose, dry throat, and fever.

In addition, the patient doesn’t need oxygen assistance, hasn’t failed to breathe yet, and was short of breath.